FGFR1 amplification is a well-known adverse prognostic factor in breast cancer, especially in hormone receptor-positive cases [25-27], and we found that FGFR1 amplification was correlated with decreased disease-free survival in the whole group and in the hormone receptor-positive subgroup, but not in the hormone receptor-negative subgroup (p=0.003, p=0.009, p=0.143, respectively). Here, NR4A1 is linked to breast carcinoma.